Electrophysiological observations in patients with motor neuron disease receiving a thyrotropin releasing hormone analogue (RX77368).
AUTOR(ES)
Guiloff, R J
RESUMO
Twenty nine patients with motor neuron disease receiving a thyrotropin releasing hormone analogue showed acute 25-30% increase in mean corrected fibre density and mean macro EMG median amplitude and area in brachial biceps muscle. The data are consistent with a direct or indirect action of the drug on anterior horn cells.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1032605Documentos Relacionados
- Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease.
- Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368).
- Comparative efficacy and safety of intravenous and oral administration of a TRH analogue (RX77368) in motor neuron disease.
- The effects of repeated administration of a long acting TRH analogue (RX77368), on TSH, T4, T3 and prolactin in patients with motor neuron disease.
- Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study.
